TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25431126

Group type: EXPERIMENTAL
Intervention: Starfix® frames
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional stereotactic frames
Number of subjects: 60
Study: 23062389

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol 320 μg/day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo/prednisone (prednisone 10 mg/day for the last 7 days)
Number of subjects: 107
Study: 19551827

Group type: EXPERIMENTAL
Intervention: BKV nephropathy patients
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Specific amino acid change (aspartic acid-to-asparagine at residue 75)
Number of subjects: 49
Study: 16823241

Group type: EXPERIMENTAL
Intervention: Continuous IV administration of NIC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous IV and oral administration of NIC
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment with NIC (Control group)
Number of subjects: 30
Study: 15678619

Group type: EXPERIMENTAL
Intervention: Avasimibe 50 mg
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Avasimibe 250 mg
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Avasimibe 750 mg
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study: 11269391

Group type: EXPERIMENTAL
Intervention: Early educational intervention (full‐time, high‐quality, educational child care from infancy to age 5)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Preschool cognitive gains
Number of subjects: 104
Study: 8978584

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg plus dexamethasone 20 mg (8 mg group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ondansetron 24 mg plus dexamethasone 20 mg (24 mg group)
Number of subjects: 80
Study: 8496472

Group type: EXPERIMENTAL
Intervention: Immediate overdentures
Number of subjects: 74

Group type: COMPARATOR
Intervention: Immediate complete dentures
Number of subjects: 74
Study: 3317935

Group type: EXPERIMENTAL
Intervention: Bromhexine hydrochloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29188425

Group type: EXPERIMENTAL
Intervention: Betrixaban for 35‐42 days
Number of subjects: 7513

Group type: EXPERIMENTAL
Intervention: Betrixaban
Number of subjects: 7513

Group type: COMPARATOR
Intervention: Enoxaparin for 10 ± 4 days
Number of subjects: 7513
Study: 26555033

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 26162481

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 210
Study: 23199009

Group type: EXPERIMENTAL
Intervention: 0.5‐1.0 μg calcitriol and 1,200 IU (30 μg) cholecalciferol
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 1,200 IU cholecalciferol
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 20572581

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with daily low-dose carboplatin (arm II)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Radiotherapy alone (arm I)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with daily low-dose carboplatin (arm II) in stage IV disease
Number of subjects: 164

Group type: COMPARATOR
Intervention: Radiotherapy alone (arm I) in stage IV disease
Number of subjects: 164
Study: 19133521

Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Local perianal nerve block (LA) with bupivacaine
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both SA and LA
Number of subjects: 67
Study: 16532872

Group type: EXPERIMENTAL
Intervention: Shin Saver orthosis treatment group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (traditional treatment)
Number of subjects: 25
Study: 14556865

Group type: EXPERIMENTAL
Intervention: Proximal coronary culprit artery lesion location
Number of subjects: 2488

Group type: EXPERIMENTAL
Intervention: Planimetered distance from the ostium to the LAD culprit lesion
Number of subjects: 2488
Study: 10696885

Group type: EXPERIMENTAL
Intervention: Ischiorectal fossa block (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No ischiorectal fossa block (Group 2)
Number of subjects: 20
Study: 9381549

Group type: EXPERIMENTAL
Intervention: 0.1 microg/kg rhIL-10
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 microg/kg rhIL-10
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10 microg/kg rhIL-10
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8472567

Group type: EXPERIMENTAL
Intervention: Blood conservation device incorporated into the arterial pressure monitoring system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with conventional arterial pressure monitoring system
Number of subjects: 100
Study: 3536293

Group type: EXPERIMENTAL
Intervention: Trientine 300 mg daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29447772

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 75-160 mg daily
Number of subjects: 1572
Study: 28241775

Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life: Mind, Body and Spirit intervention, delivered through eight lessons during a summer basketball camp and one lesson with parent/trusted adult.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition, details not specified.
Number of subjects: 0
Study: 25941174

Group type: EXPERIMENTAL
Intervention: Daily ozone levels on the day before a PCV
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: 3-day mean ozone levels before a PCV
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Daily PM2.5 levels on the day before a PCV (December to March)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Hours of sunshine (September to November)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Atmospheric pressure (April to June)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Temperature (April to August)
Number of subjects: 1447
Study: 23258435

Group type: EXPERIMENTAL
Intervention: Waterglass Intervention Program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Private tutoring (Control)
Number of subjects: 46
Study: 22007711

Group type: EXPERIMENTAL
Intervention: Dedicated Education Unit (DEU) model with clinical teacher mentoring
Number of subjects: 12
Study: 18438215

Group type: EXPERIMENTAL
Intervention: 20‐second WAnT protocol
Number of subjects: 96
Study: 16615715

Group type: EXPERIMENTAL
Intervention: Visual Imagery (VI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-Vision (FV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-Vision (NV)
Number of subjects: 0
Study: 15504288

Group type: EXPERIMENTAL
Intervention: Sequence administration of lamivudine and interferon alpha 1b
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Interferon alpha 1b
Number of subjects: 150

Group type: COMPARATOR
Intervention: No anti-virus therapy (control group)
Number of subjects: 150
Study: 11083676

Group type: EXPERIMENTAL
Intervention: Usual setting (U) of NPSV, IPS 16 +/- 3 cm H(2)O, PEEPe 3.6 +/- 1.4 cm H(2)O
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Physiologic setting (PHY) of NPSV, IPS 15 +/- 3 cm H(2)O, PEEPe 3.1 +/- 1.6 cm H(2)O
Number of subjects: 23
Study: 9307197

Group type: EXPERIMENTAL
Intervention: Preradiation chemotherapy consisting of methotrexate 120 mg/m2, cisplatin 100 mg/m2, 5-fluorouracil 1000 mg/m2 for five days, leucovorin 25 mg/m2 every six hours for 6 doses, followed by radiation therapy and adjuvant IFN-beta (10^5 U/kg) 3 times a week for 6 months.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Radiotherapy with a cumulative dose of 59.4 Gy to primary sites and 45 Gy to the neck area.
Number of subjects: 22
Study: 8354807

Group type: EXPERIMENTAL
Intervention: Central administration of adenosine (3 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Central administration of adenosine (6 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Central administration of adenosine (9 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peripheral administration of adenosine (3 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peripheral administration of adenosine (6 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peripheral administration of adenosine (9 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peripheral administration of adenosine (12 mg)
Number of subjects: 30
Study: 3575578

Group type: EXPERIMENTAL
Intervention: Family management approach
Number of subjects: 36

Group type: COMPARATOR
Intervention: Individual management approach
Number of subjects: 36
Study: 31714397

Group type: EXPERIMENTAL
Intervention: Pedometer Feedback (PF)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Pedometer Feedback + Motivational Messaging (PF + MM)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Motivational Messaging (MM)
Number of subjects: 99
Study: 31230831

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 0
Study: 27989691

Group type: EXPERIMENTAL
Intervention: Aquatic training program once per week for six weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Land-based training program once per week for six weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Aquatic training program
Number of subjects: 51

Group type: COMPARATOR
Intervention: Land-based training program
Number of subjects: 51
Study: 25577748

Group type: EXPERIMENTAL
Intervention: Adenosine stress SPECT MPI
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual clinical cardiac risk classification
Number of subjects: 272
Study: 24101860

Group type: EXPERIMENTAL
Intervention: Betesil® plaster applied for 12 hours immediately after the procedure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aescin 10% cream applied immediately after the procedure, in the evening, and the morning after
Number of subjects: 20
Study: 21843889

Group type: EXPERIMENTAL
Intervention: 21 active pills + 7 placebo pills (21/7 COC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 24 active pills + 4 placebo pills (24/4 COC)
Number of subjects: 60
Study: 20923537

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin
Number of subjects: 13
Study: 17885297

Group type: EXPERIMENTAL
Intervention: High maternal CRP concentration (> 10 mg/l)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Maternal CRP concentration
Number of subjects: 606
Study: 15153210

Group type: EXPERIMENTAL
Intervention: Ketamine 6 mg.kg(‐1) per oral
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sour cherry juice alone
Number of subjects: 80
Study: 11445752

Group type: EXPERIMENTAL
Intervention: POST
Number of subjects: 15

Group type: COMPARATOR
Intervention: CON
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PRE
Number of subjects: 15
Study: 9564606

Group type: EXPERIMENTAL
Intervention: Selegiline (10, 30, or 60 mg/day for three or more weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pargyline (90 mg/day for three or more weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clorgyline (30 mg/day for three or more weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selegiline (higher doses than 10 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selegiline and Pargyline (highest doses)
Number of subjects: 0
Study: 7816786

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control NSAIDs
Number of subjects: 900
Study: 3055740

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Day hospital treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Home treatment
Number of subjects: 109
Study: 30522389

Group type: EXPERIMENTAL
Intervention: Self-reported disability measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobility performance measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive measures
Number of subjects: 0
Study: 31362061

Group type: EXPERIMENTAL
Intervention: OLE treatment
Number of subjects: 419

Group type: COMPARATOR
Intervention: Standard respiratory care (Control)
Number of subjects: 419
Study: 28708931

Group type: EXPERIMENTAL
Intervention: Clofarabine (CIA)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Fludarabine (FIA)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Idarubicin and cytarabine (historical control)
Number of subjects: 182
Study: 26299740

Group type: EXPERIMENTAL
Intervention: Panitumumab + mFOLFOX6
Number of subjects: 1

Group type: COMPARATOR
Intervention: Bevacizumab + mFOLFOX6
Number of subjects: 1
Study: 23980349

Group type: EXPERIMENTAL
Intervention: Xiaozhi Capsule (XZC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Xuezhikang Capsule (XZKC)
Number of subjects: 120
Study: 20827664

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Baseline 2 h glucose levels in oGTT
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Body weight change
Number of subjects: 128
Study: 17853008

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/daily for 4 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diclofenac 100 mg on demand for 4 weeks plus levofloxacin 250 mg daily for the first week
Number of subjects: 90
Study: 16597040

Group type: EXPERIMENTAL
Intervention: Naftopidil (25 mg once a day for 4 weeks)
Number of subjects: 106
Study: 12809971

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/d
Number of subjects: 1000
Study: 11001109

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (7VPnC) administered as a separate injection
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (7VPnC) combined with Haemophilus influenzae type b vaccine (HbOC)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Routine vaccines only (control group)
Number of subjects: 368
Study: 9111873

Group type: EXPERIMENTAL
Intervention: Equal mixture of Cupressus sempervirens and Cryptomeria japonica pollen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8464252

Group type: EXPERIMENTAL
Intervention: Early discharge planning from day 3 of hospital stay (n = 417)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Standard discharge planning only with written physician request (n = 418)
Number of subjects: 835
Study: 6705277

Group type: EXPERIMENTAL
Intervention: 3 injections of 1 ml (Group I)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 3 injections of 2 ml (Group II)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 4 injections of 1 ml (Group III)
Number of subjects: 215
Study: 30823913

Group type: COMPARATOR
Intervention: Home-based exercise training programme using minimal equipment, conducted six days per week with coaching from a health care professional during three home visits and regular telephone calls over one year.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Home-based exercise training programme using minimal equipment.
Number of subjects: 120
Study: 30126781

Group type: EXPERIMENTAL
Intervention: Negative pressure therapy (Prevena)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard gauze dressing
Number of subjects: 119
Study: 27423166

Group type: EXPERIMENTAL
Intervention: 16-week Internet-based cognitive-behavioral intervention
Number of subjects: 139

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 139
Study: 24705980

Group type: EXPERIMENTAL
Intervention: Gemcitabine-docetaxel (GD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine-docetaxel (CD)
Number of subjects: 0
Study: 19875317

Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy (BSSO)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mandibular distraction osteogenesis (MDO)
Number of subjects: 14
Study: 16269641

Group type: EXPERIMENTAL
Intervention: Fibrinogen levels
Number of subjects: 6713

Group type: COMPARATOR
Intervention: C-reactive protein levels
Number of subjects: 6713
Study: 11355380

Group type: EXPERIMENTAL
Intervention: Combined task (color and position cues)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard task (position cue)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-standard task (color cue)
Number of subjects: 0
Study: 9531078

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy followed by simultaneous resection of primary and metastatic lesions (when feasible) and further chemotherapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simultaneous surgical treatment of primary and metastatic tumor
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall treatment including chemotherapy and surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison with contemporary patients with localized disease
Number of subjects: 44
Study: 8033492

Group type: EXPERIMENTAL
Intervention: Intravenous torsemide
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral torsemide
Number of subjects: 48
Study: 2688405

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 1092576

Group type: EXPERIMENTAL
Intervention: Attenuated influenza virus vaccine (ANN strain)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 30280651

Group type: EXPERIMENTAL
Intervention: M72/AS01E
Number of subjects: 1786

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1786
Study: 27278062

Group type: EXPERIMENTAL
Intervention: Bilateral STN-DBS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Right-sided STN-DBS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Left-sided STN-DBS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unilateral STN-DBS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Off stimulation
Number of subjects: 22
Study: 25008799

Group type: COMPARATOR
Intervention: Naso-gastric infusion of 500mL/0kJ water (Stomach distention)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Naso-gastric infusion of 500mL/1770kJ chocolate milk (Stomach distention with caloric content)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral administration of 500mL/1770kJ chocolate milk (Stomach distention with caloric content and oral exposure)
Number of subjects: 14
Study: 22656075

Group type: EXPERIMENTAL
Intervention: Comprehensive training package including frame-of-reference and rater error training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard training package involving overview, modeling, practice, and feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More intensive training package
Number of subjects: 0
Study: 21050539

Group type: EXPERIMENTAL
Intervention: Older SSc patients
Number of subjects: 264
Study: 18545166

Group type: EXPERIMENTAL
Intervention: Swiss ball
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Wobble board
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dyna Disc
Number of subjects: 16

Group type: COMPARATOR
Intervention: BOSU ball
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stable base
Number of subjects: 16
Study: 15705690

Group type: EXPERIMENTAL
Intervention: Rectal artemether
Number of subjects: 103

Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 103
Study: 14514538

Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aero position
Number of subjects: 10
Study: 10368486

Group type: EXPERIMENTAL
Intervention: Sequential use of instruments (vacuum first, then forceps, or vice versa)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vacuum group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Forceps group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sequential group
Number of subjects: 34
Study: 8888321

Group type: EXPERIMENTAL
Intervention: 2.5-mg silver acetate lozenge
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 500
Study: 2058340

Group type: EXPERIMENTAL
Intervention: Latamoxef 2 g single-dose prophylaxis
Number of subjects: 190

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 190
Study: 6093312

Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline aerosol (Control)
Number of subjects: 21
Study: 31395391

Group type: EXPERIMENTAL
Intervention: e-learning program
Number of subjects: 388
Study: 29026961

Group type: EXPERIMENTAL
Intervention: Extracorporeal subtotal septal reconstruction (ECS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: In situ septoplasty with asymmetric spreader grafts (ISS)
Number of subjects: 40
Study: 26742606

Group type: COMPARATOR
Intervention: Comprehensive care (n=99)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Interdisciplinary care (n=101)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care (control) (n=99)
Number of subjects: 299
Study: 24528484

Group type: EXPERIMENTAL
Intervention: Group-based self-management course
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22983369

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warm Water (WW)
Number of subjects: 20
Study: 20595283

Group type: EXPERIMENTAL
Intervention: Exercise-based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-based intervention
Number of subjects: 0
Study: 17184370

Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prompted voiding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Habit retraining
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timed voiding
Number of subjects: 0
Study: 15923248

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate withdrawal (S)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Combined treatment with salmeterol and fluticasone propionate (SFC)
Number of subjects: 497